Log In
BCIQ
Print this Print this
 

tucatinib (ONT-380) (formerly ARRY-380)

  Manage Alerts
Collapse Summary General Information
Company Array BioPharma Inc.
DescriptionSmall molecule oral epidermal growth factor receptor 2 (HER2; EGFR2; ErbB2; neu) inhibitor
Molecular Target Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu)
Mechanism of ActionEpidermal growth factor (EGF) receptor 2 (HER2) (ErbB2) (neu) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationBreast cancer
Indication DetailsTreat HER2-positive metastatic breast cancer
Regulatory Designation U.S. - Fast Track (Treat HER2-positive metastatic breast cancer)
PartnerCascadian Therapeutics Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$310.0M

$30.0M

$280.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

12/12/2014

$300.0M

$20.0M

$280.0M

06/03/2013

$10.0M

$10.0M

0

Get a free BioCentury trial today